Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
...s were written for opioids in 2007 in the United States alone. Currently, there are no oral drugs approved that are indicated to treat OIC. OBD and oic
can significantly impact quality of life and increase healthcare utilization.
1. Panchal SJ, Muller-Schwefe P, Wurzelmann JI. Opioid-induce...
New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
... The clinical study showed that significantly more oic
advanced illness experienced bowel m...nstrate that RELISTOR has the
potential to relieve oic
effectively, but that it does so without
interferi...y and safety of subcutaneous RELISTOR in relieving oic
patients with an advanced illness. Co-primary e...
Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations
approved RELISTOR subcutaneous injection for the treatment of oic
patients with advanced illness who are receiving palliative care, when
r...e bromide injection) for subcutaneous use is indicated for
the treatment of oic
in patients with advanced illness receiving palliative
care. Applications a...
NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting
...OIC. Stool softeners or laxatives may be ineffective for many
patients with oic
and they are often associated with side effects like
diarrhea and stomach cramps. OBD and oic
can significantly impact quality
of life and increase healthcare utilizatio...
Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
...re excited to begin our Phase 2 clinical trial for oral NKTR-118
in OBD and oic
patient settings," said Hoyoung Huh, M.D., Ph.D. Chief
Operating Officer an... OBD. Stool
softeners or laxatives may be inadequate for many patients with oic
often are associated with unwanted side effects such as bloating and
Progenics and Wyeth Announce Positive Results from Three-Month
Clinical-Extension Study of Subcutaneous Methylnaltrexone for the
Treatment of Opioid-Induced Constipation in Patients with Advanced
... Symposium in St. Gallen,
patients completed a placebo-controlled phase 3
st...red as needed, for up to
patients received subcutaneous methylnaltrexone
antagonist that is designed to treat oic
without interfering with
pain relief. Currently, t...